# Scenic Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scenic-biotech-b-v

- Industry: Biotechnology
- Headquarters: Amsterdam, Netherlands
- Website: www.scenicbiotech.com
- Total disclosed funding: $38M
- Latest round: Series A (Mar 10, 2022)
- Investors on record: 6

## About

Scenic Biotech B.V. is a biotechnology company focused on developing innovative modifier therapies for genetic disorders, utilizing its proprietary Cell-Seq platform to identify modifier genes that offer therapeutic benefits.Founded in 2017 in Amsterdam, Netherlands, Scenic Biotech B.V. specializes in pioneering therapeutic solutions for genetic disorders. The company was co-founded by Sebastian Nijman and Thijn Brummelkamp, and is currently led by CEO Oscar Izeboud. Scenic Biotech has successfully raised EUR 28.000 mn in Series A funding on March 10, 2022, attracting notable investors such as BioGeneration Ventures, BioMed Partners, Eir Ventures, Inkef Capital, Oxford Sciences Enterprises, and Vesalius Biocapital. The firm has secured a total of 3 deals to date.Scenic Biotech specializes in the development of a pioneering therapeutic approach known as modifier therapy, aimed at treating genetic disorders linked to neuro- and metabolic diseases. Their core offerings focus on identifying and leveraging modifier genes, which act as "hidden disease protection factors" to counteract the effects of primary disease-causing mutations. This innovative methodology allows for the rebalancing of health by modulating alternative genomic functions rather than directly targeting the original mutations. The company employs its proprietary Cell-Seq platform to discover these modifier genes, facilitating the creation of a diverse pipeline of novel therapeutics. Scenic Biotech collaborates with major pharmaceutical companies like Genentech and Bristol Myers Squibb, targeting markets across North America and Europe, where it aims to address unmet medical needs among patients suffering from genetic disorders.Scenic Biotech's revenue structure is primarily driven by strategic partnerships and collaborations with established pharmaceutical companies. Transactions typically occur through collaborative agreements that may encompass research and development funding, milestone payments, and royalties from product sales. The firm’s partnerships facilitate the advancement of its therapeutics pipeline, with a focus on modifier therapy, which is a unique class of treatment that addresses complex genetic disorders. While specific pricing plans for individual products or services are not disclosed, the company’s revenue generation is supported by the commercial success of its pipeline candidates once they reach market readiness. Through these collaborative efforts, Scenic Biotech aims to establish a sustainable financial model that aligns with its mission to innovate in the field of genetic medicine.Following the EUR 28.000 mn raised in Series A funding in March 2022, Scenic Biotech plans to advance its transition into a development-stage company and bolster its existing pipeline. The funding will support the creation of new programs based on its Cell-Seq genetic modifier target discovery platform, which is expected to lead to new industry collaborations. The company is also looking to expand its market presence across Europe and North America, targeting areas with significant unmet medical needs, although specific new product release dates and further market expansion timelines have not been disclosed.

## Funding rounds

- Series A, Mar 10, 2022, $31M — BioMed Partners, BioGeneration Ventures, Vesalius Biocapital, Inkef, Oxford Sciences Enterprises, Eir Ventures
- Series A, May 6, 2017, $7.1M — BioGeneration Ventures, Inkef, Oxford Sciences Enterprises

## Investors

- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Series A
- Inkef (https://capitalatlas.ai/funds/inkef) — Series A
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series A
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series A
- Eir Ventures (https://capitalatlas.ai/funds/eir-ventures) — Series A